Context: Isolated hypogonadotropic hypogonadism (IHH), characterized by gonadotropin deficiency and absent puberty, is very rare in women. IHH prevents pubertal ovarian stimulation, but anti-Müllerian hormone (AMH) and antral follicle count (AFC) have not been studied.
I
solated hypogonadotropic hypogonadism (IHH) and Kallmann syndrome (KS) are rare genetic diseases due to deficient gonadotropin-releasing hormone (GnRH) secretion or action (1) . Their prevalence appears to be lower in females (estimated at 1/10,000 to 1/50,000) than in males (1, 2) . Patients with IHH/KS have a profound chronic deficit, both prenatally and postnatally, in the two pituitary gonadotropins [luteinizing hormone (LH) and follicle-stimulating hormone (FSH)], which generally persists throughout life (3) . In females, IHH/KS is usually diagnosed in the teenage years, because of primary amenorrhea with absent or partial breast development, depending on the severity of the deficit in gonadotropins and, thus, in ovarian steroids (1, 2) . Apart from two isolated cases (4, 5) , anti-Müllerian hormone (AMH) has not been evaluated in women with IHH/KS. Similarly, ovarian morphology, and especially the number of antral follicles (AFs), has not been precisely studied in this setting. Nevertheless, IHH/KS is an ideal model for analyzing the ovarian consequences of chronic gonadotropin deficiency. It also allows the physiological role of pituitary gonadotropins to be studied in terms of both ovarian peptide and steroid hormone secretion and follicle growth (6) (7) (8) . The aims of this study were to evaluate ovarian AMH and inhibin B (InhB) levels and the number of AFs in a significant number of wellphenotyped women with IHH/KS compared with healthy matched controls. Accordingly, we evaluated the response of sex steroids and of these two ovarian peptides to recombinant human FSH (rhFSH) administration, and we studied their relationship with the number and growth of AFs in a subset of these patients affected by severe gonadotropin deficiency. We also had the opportunity to compare the ovarian hormonal response in these latter patients to that of similar IHH/KS women having received combined rhFSH plus recombinant human LH (rhLH) therapy.
Controls, Patients, and Methods

Healthy controls
Healthy female volunteers aged over 18 years, recruited through the press, were included after a thorough history and clinical examination between March 2010 and October 2015. This control population consisted of 51 healthy women aged from 21 to 36 years with normal thyroid hormone, insulin-like growth factor 1 (IGF-1), and prolactin levels, as well as a normal body mass index (BMI) ( Table 1 ). All healthy control women had a normal age of pubertal onset (12 to 14 years) and regular spontaneous menstrual cycles (27 to 31 days), and they had ovulated in the cycle preceding the evaluation, as confirmed by progesterone levels .6.0 ng/mL. None of these normal women had clinical evidence of androgen excess and none exercised excessively/intensively. These healthy controls were studied between days 3 and 6 after menses onset of a spontaneous cycle, at which time clinical examination, blood sampling, and transvaginal ovarian ultrasound were completed.
IHH/KS patients
All 68 women with IHH/KS included in this study were at least 18 years old at the time of evaluation (Table 1) . At diagnosis, they had low to low-normal estradiol (E2) levels, low or inappropriately normal gonadotropin levels, no other pituitary hormone deficiencies (normal free thyroxine 4, thyrotropin, and IGF-1 and normal cortisol and GH responses to hypoglycemic challenge), normal to low serum prolactin levels, and no neuroanatomic [normal hypothalamo-pituitary magnetic resonance imaging (MRI)] or functional cause of hypogonadotropic hypogonadism. None of the IHH/KS women had an eating disorder, and all had BMI values $22 kg/m 2 (range, 22 to 26 kg/m 2 ). Their body fat composition, determined by dual-energy X-ray absorptiometry, was also normal (21% to 25%/weight). None of the patients exercised excessively/intensively. None had clinical evidence of androgen excess. Thirty-eight of the patients were considered to have KS, as olfactory testing (a rapid computerassisted olfactory test to measure detection thresholds for five pure odorants) showed anosmia or hyposmia and/or because MRI showed olfactory bulb aplasia or hypoplasia (9) . Six additional IHH/KS women (25 to 28 years of age) having received combined gonadotropin therapy were also included.
Protocols
The study was approved by the Institutional Review Board of Bicêtre teaching hospital (P081216/IDRCB 2009 A00892-55 and PHRC-2009 PHRC- -2015 , and all participants provided informed consent before inclusion.
The 68 IHH/KS patients were enrolled between November 2009 and March 2016. In 21 cases, initial basic hormonal profiling was performed at diagnosis, before any replacement therapy. In the remaining 47 cases, hormonal profiling and sonography were performed at least 3 months after discontinuation of estrogen/progestagen replacement. Only women who did not develop spontaneous menses after discontinuing replacement therapy were included, to exclude those whose gonadal axis might have recovered (reversible forms) (10) . In addition to the 68 KS/IHH women discussed earlier, six IHH/KS patients were included who wanted to conceive and who were referred between March 2012 and June 2015 for ovulation induction.
Ovarian stimulation with rhFSH
With their informed consent, rhFSH was administered to 12 patients who wanted to assess their fertility. This subset had low AMH levels (4.1 to 11.4 pmol/L, see Results), and their previous gynecologists had informed them that they had little chance of conceiving based on AMH cut-offs in women with an intact, hypothalamic-pituitary-ovarian axis (11, 12 /mL, normal morphology and mobility percentages). In these six patients, treatment initially comprised 75 to 150 IU of rhFSH (GONAL-f ® or Puregon ® ) and 75 IU of rhLH (Luveris ® , Merck Serono) (13, 14) , with the doses then being titrated to the patients' responses. Treatment was individualized and monitored by serum E2 assay and ovarian ultrasound every 4 days. Briefly, the mean daily dose (IU) regimens for rhFSH and rhLH, respectively, were as follows: 131 6 31 (range, 75 to 150) and 75 6 0.0 from day 0 to day 4, 144 6 15 (112.5 to 150) and 137.5 6 19 (112.5 to 150) from day 5 to day 8, and 81 6 14 (75 to 112.5) and 150 6 41 (112.5 to 225) from day 9 to day 12.
Recombinant human chorionic gonadotropin (Ovitrelle ® , Merck Serono) (250 to 500 mg subcutaneously) was given when a single dominant follicle .16 mm was detected, with a concomitant E2 level .350 pg/mL (mean, 449 6 62; range, 350 to 512 pg/mL). Luteal-phase support consisted of subcutaneous recombinant human chorionic gonadotropin or vaginal progesterone. The cycle was cancelled when there were more than two dominant follicles on ovarian ultrasonography (OvUS).
Ovarian ultrasound examination
Transvaginal ultrasonography was not possible in 29 of the 68 IHH/KS patients, because of virginity or refusal. OvUS was performed in the remaining 39 untreated patients at an unspecified time (amenorrheic women) and in 41 healthy controls in the early follicular phase, 3 to 6 days after menses onset. OvUS was always performed on the same day as blood sampling.
Transvaginal OvUS was performed in patients and controls by the same experienced ovarian ultrasonographer (J.-M.L.), using a Voluson E8 Expert device (BT13, 3D-4D; General Electric Systems, Velizy, France) equipped with a 6-to 12-MHz transvaginal transducer. Ultrasound measurements were made in real time, using a standardized protocol. The highest possible magnification was used to examine the ovaries. Each OV was estimated as p/6 (transverse diameter) 3 (anteroposterior diameter) 3 (longitudinal diameter) (ellipsoid). Each AF ($2 mm) was identified and then measured as the mean of two diameters. The OV and the AF count (AFC) data used for statistical analysis were the mean of the values for the left and right ovaries.
Hormone assays
Fasting blood samples were drawn between 8:00 AM and 10:00 AM from an antecubital vein and immediately centrifuged at 4°C. Serum was stored at 280°C until assayed. To avoid interassay variability, all hormone assays were performed during the same run with frozen (280°C) samples. Serum InhB levels were measured with the Beckman Coulter Generation II assay (Beckman Coulter, Marseilles, France), with a detection limit of 3 pg/mL and intra-assay and interassay coefficients of variation (CVs) of 6% and 11%, respectively, at 15 pg/mL. Serum AMH was measured using an enzymatically amplified two-site immunoassay (AMH Generation II enzyme-linked immunosorbent assay; Beckman Coulter) according to the manufacturer's recommendations. The detection limit was 0.7 pmol/L. The mean interassay CV was 8.6%, and the mean intra-assay CV was 4.0% at 22 pmol/L. Serum FSH and LH were measured using a sensitive immunoradiometric assay (CIS Bio International, Gif-sur-Yvette, France), with a detection limit of 0.05 IU/L for both hormones (IU/L, second International Reference Preparation World Health Organization 78/549 for FSH; IU/L, first International Reference Preparation 68/40 for LH). The intra-assay and interassay CVs were 1.5% and 5.2% for LH and 2.7% and 5.5% for FSH, using quality control (QC) sera measuring 3.5 and 3.9 IU/L, respectively. E2, androstenedione (ADIONE), and testosterone (T) were assayed simultaneously in the two groups of subjects using gas chromatography/mass spectrometry, after extraction and derivatization, as described in detail by Giton et al. (15) . The lower limits of detection and the intra-assay and interassay CVs were 2.4 pg/mL and 7.9%/9.5%, respectively, for E2 using QC sera measuring 2.7 pg/mL; 0.05 ng/mL and 2.2%/3.1% for T using QC sera measuring 0.48 ng/mL; and 0.049 ng/mL and 4.6%/5.2% for ADIONE using QC sera measuring 0.15 ng/mL.
Statistical analyses
All results are reported as individual values in the figures and as mean 6 standard deviation (SD) in Table 1 and in the text. Hormonal parameters were compared by using a parametric t test or the Mann-Whitney, Wilcoxon, or KolmogorovSmirnov nonparametric test as appropriate. We used one-way repeated-measures analysis of variance to assess the ovarian response to rhFSH or to rhFSH plus rhLH, using ovarian hormone or AFC as dependent variables. Appropriate post hoc pairwise comparisons were performed. A Spearman rank correlation procedure was used to define the serum AMH values that correlated with OV and AFC. P values of ,0.05 were considered to denote statistical significance.
Results
Basal gonadotropin and sex steroid levels
Individual serum FSH, LH, E2, ADIONE, T, InhB, and AMH values are shown in Fig. 1 . Both FSH and LH were significantly lower in the IHH/KS patients than in the controls. E2 levels were also significantly lower in the patients than in the controls, but they were nonetheless well above the detection limit of this sensitive steroid assay. Both ADIONE and T levels were slightly but significantly lower in the patients than in the controls.
Serum InhB levels were significantly lower in the patients than in the controls [ Fig. 1(e) ]. Only 11 of 68 patients had InhB values above the lowest observed control value. The average InhB level (pg/mL) was lower among patients with serum FSH levels below 1 IU/L than among patients with higher FSH levels (7.4 6 3.8 vs 16.1 6 9.5; P , 0.001). Likewise, the mean serum InhB level was significantly lower among patients with E2 levels of 12 pg/mL or less than among patients with higher E2 levels (8.1 6 4.2 vs 19.2 6 10.9; P , 0.001).
AMH levels (pmol/L) were also significantly lower in the patients than in the controls [ Fig. 1(f) ]. However, we stress that two-thirds of the patients (44/68) had AMH levels above the lowest observed control value. The mean AMH level was lower among patients with FSH levels ,1 IU/L than among patients with higher FSH levels (14.1 6 7.2 vs 32.5 6 10.7; P , 0.001).
OvUS
Mean (6SD) OV was very significantly lower in the patients than in the controls (1.54 6 0.55 vs 6.02 6 2.05 mL; P , 0.0001) [ Fig. 2(a) ]. Mean OV was lower among patients with serum FSH levels , 1.0 IU/L than among patients with higher FSH levels (1.1 6 0.2 vs 1.9 6 0.5 mL; P , 0.001). The mean total AF number per ovary was significantly lower in the patients than in the controls (3.67 6 1.9 vs 12.0 6 4.8; P , 0.001) [ Fig. 2(b) ]. Furthermore, the total AF number per ovary was lower in patients with FSH levels , 1 IU/L than in patients with higher levels (2.1 6 1.2 vs 4.4 6 1.3; P , 0.001). Likewise, the numbers of small (#6 mm) follicles (3.2 6 1.9 vs 6.9 6 3.9; P , 0.001) and large follicles (.6 mm) (0.45 6 0.7 vs 5.0 6 2.7; P , 0.001) were lower in the patients than in the controls [ Fig. 2(c) and 2(d) ]. The number of small AF number per ovary was lower in patients with circulating FSH , 1.0 IU/L than in patients with higher FSH levels (1.4 6 1.4 vs 3.9 6 1.6; P , 0.001).
Ovarian aspect and circulating AMH
In IHH/KS serum AMH levels correlated positively with OV (r = 0.543, P , 0.001) and with the total number of follicles (r = 0.553, P , 0.001). Serum AMH also correlated positively with the number of small (#6 mm) follicles (r = 0.41, P , 0.001).
Effect of rhFSH on ovarian hormone levels and follicle counts
Individual changes in serum FSH, E2, T, InhB, and AMH in the 12 IHH/KS patients with severe gonadotropin deficiency after treatment with rhFSH are shown in Fig.  3(a-e) . rhFSH administration induced a sustained elevation of plasma FSH levels (from 0.15 6 0.08 to a peak of 9.4 6 2.57 IU/L; F 103.4, P , 0.0001) in the treated women, confirming their adherence to FSH therapy [ Fig.  3(a) ]. From the eighth day of FSH therapy, serum FSH levels stabilized as a result of lowering of doses administered.
FSH administration did not affect LH levels (0.34 6 0.28 before, 0.31 6 0.23 IU/L during).
During rhFSH therapy there was a marked increase in serum E2 from 7.6 6 2.9 to 104.4 6 22.0 pg/mL; P , 0.0001 [ Fig. 3(b) ] with no increase in plasma T [ Fig. 3(c) ]. InhB increased with FSH treatment from 6.8 6 2.9 to 190.8 6 21.7 pg/mL; P , 0.0001 [ Fig. 3(d) ]. A marked increase in AMH was evident by day 4 of rhFSH administration, followed by a slight but significant decline on day 12 [ Fig. 3(e) ]. Changes in the mean AFC during rhFSH therapy are shown in Fig. 3(f) . Interestingly, the number of larger follicles (.6 mm) rose significantly from 0.4 6 0.7 before rhFSH to 4.2 6 1.8 on day 4, and continued to increase significantly on day 8 (6.2 6 1.9), reaching a maximum on day 12 (8.0 6 1.4) in spite of a decrease in FSH doses administered. The number of smaller follicles (#6 mm) also rose significantly between days 0 and 4 from 2.8 6 1.4 to 5.9 6 1.8 but then fell to 4.4 6 1.2 on day 8 and 4.0 6 1.0 on day 12.
Comparative effects of rhFSH alone and combined rhFSH plus rhLH on ovarian hormone levels in women with IHH/KS
Comparison of changes in mean (6SD) serum FSH, LH, E2, T, InhB, and AMH in the 12 IHH/KS patients having received rhFSH alone vs the six IHH/KS patients treated with combined rhFSH plus rhLH for ovulation induction are shown in Fig. 4 . A significant and similar increase in mean serum FSH levels was observed during both rhFSH and rhFSH plus rhLH administration. Whereas rhFSH administered alone did not affect either mean LH or mean T levels, in IHH/KS patients who underwent the combined rhFSH plus rhLH treatment, mean serum LH and mean T increased significantly [ Fig. 4(b) and 4(c) ]. In parallel, when compared with IHH/KS patients having received rhFSH alone, the increase in mean serum E2 levels was significantly and sharply higher in patients who received rhFSH plus rhLH combination therapy [ Fig. 4(d) ]. In contrast, the significant increase in both mean serum InhB and mean AMH levels was similar during both rhFSH alone and during combined rhFSH plus rhLH administration [ Fig. 4 (e) and 4(f)].
Ovulation and conception in the six KS patients with low serum AMH levels and low AF numbers
In the six KS patients with low AMH levels who underwent ovulation induction with rhFSH and rhLH, ovulation occurred after two to four cycles of stimulation. Five of these patients, who had programmed intercourse before and at the time of triggered ovulation, conceived and gave birth to a healthy baby (no twin pregnancies).
Discussion
The relationship between circulating AMH levels and ovarian morphology, including the number of AFs, has mainly been studied in women with polycystic ovary disease (11) or ovarian failure (12, 16 ) during ovulation stimulation with or without GnRH analogs (17, 18) and, more rarely, in healthy prepubescent girls (17, 19) . In contrast, only anecdotal reports (4, 5) are available for women with IHH/KS. This lack of published data is probably due to the rarity of IHH/KS in females (1, 2). However, this disease represents a unique model, given the presence of isolated gonadotropin deficiency and normal levels of other anterior pituitary hormones, as it begins in the antenatal period and continues through the neonatal and postnatal periods, persisting into adulthood with rare exceptions (3, (6) (7) (8) .
Thus, the first aim of this study was to study AMH and other ovarian hormones, as well as OV, and the number of AFs in a large group of women with IHH/KS compared with healthy cycling control-matched women.
In line with a previous report that used a radioimmunoassay (2), we observed in the present study very low E2 levels in untreated IHH/KS women. This deficiency in ovarian E2 secretion was caused by the combined effects of FSH and LH insufficiencies. First, FSH is essential to stimulate aromatase in ovarian granulosa cells. Second, LH deficiency in women with IHH/KS can be responsible for a relative androgen deficiency. Indeed, low circulating ADIONE and T levels demonstrated in the present study are probably consecutive to inadequate stimulation of internal theca cells by low circulating LH. This hypothesis was confirmed by the increase in T levels during combined rhLH plus rhFSH stimulation of IHH/KS women whereas FSH had no effect. Data provided in the present study also showed a larger increase in serum E2 in IHH/KS women receiving rhFSH plus rhLH when compared with those stimulated with rhFSH alone. This reinforces the importance of LH deficiency in IHH/KS and its replacement requirement (6-8, 13, 14) . A sufficient elevation of E2 during ovulation induction is indeed essential to ensure both sufficient development of the endometrium and adequate secretion of cervical mucus, with both being mandatory for sperm passing through the cervix and for a embryo implantation and necessary for obtaining an ongoing pregnancy (13, 14) .
In addition to low levels of FSH, LH, and E2, circulating InhB levels were also very low in KS/IHH women. Moreover, InhB levels were particularly low in the subgroup of women with the lowest FSH levels. This suggests that InhB reflects the severity of FSH deficiency in IHH/KS women, as previously reported in men with this disease (1). The low InhB concentrations observed in these patients are similar to those described in normal girls before the pubertal increase in gonadotropins (19) (20) (21) . Although the patients with IHH/KS have concomitant deficiencies in both FSH and LH, our findings indicate that abnormal ovarian inhB secretion in these patients is due mainly to their FSH deficiency. This assumption is consistent almost undetectable serum InhB observed in women with isolated complete FSH deficiency due to FSH-b gene mutation, despite elevated LH levels (4). The principal dependency of ovarian InhB secretion on FSH in the IHH/KS women included in this study was also clearly suggested by the InhB response to rhFSH administration in the absence of an increase in LH and was reinforced by the lack of additional InhB stimulation in IHH/KS women having received rhFSH plus rhLH. Furthermore, these results are consistent with the early follicular phase dependency of InhB on FSH, but not LH, in normal women in whom endogenous gonadotropins were suppressed by a GnRH agonist (22, 23) . The low inhB levels in our patients were also associated with low E2 levels, as the average InhB level was significantly lower in the subgroup of patients with the most pronounced E2 deficiency. This in vivo finding is consistent with the positive correlation reported between E2 and InhB concentrations in antral follicular fluid (24) .
We also found that circulating AMH concentrations were significantly lower in women with IHH/KS than in healthy controls. This clearly shows the dependency of circulating AMH levels on gonadotropins, as suggested by the decrease in AMH levels in women whose gonadal axis is inhibited by GnRH antagonists or agonists (17) . However, almost two-thirds of our IHH/KS patients had serum AMH levels within the control range. Interestingly, the subgroup of IHH/KS women with the lowest FSH levels had significantly lower AMH levels than those with higher FSH levels, indicating that the low levels of AMH are also linked to the severity of FSH deficiency. The correlation between OV and the AMH concentration also favors a relationship between the severity of gonadotropin deficiency and the AMH level.
In the present study we have shown that AMH levels in KS/IHH patients in the absence of FSH stimulation are lower than in cycling control women in contrast to AMH , and (e and f) the ovarian peptides InhB and AMH levels in women with IHH/KS treated with either rhFSH alone (n = 12; C) or with combined rhFSH plus rhLH (n = 6; n). In the subgroup receiving rhFSH alone, IHH/KS patients and rhFSH dose regimen are the same as those described in Fig. 3 [shown here are mean (6SD) serum hormones levels instead of individual values]. In the six IHH/KS women having received combined gonadotropin therapy, the detail of rhFSH and rhLH dose regimens are indicated in patients and methods section. LLN, lower limit of normal; ULN, upper limit of normal. levels in women with acquired gonadotropin deficiency secondary to functional hypothalamic amenorrhea or to hyperprolactinemia (25, 26) , in whom AMH concentrations are similar to those of normal women. Two factors could account for this difference. The first is the greater severity of chronic gonadotropin (especially FSH) deficiency in IHH/KS. Second, the very prolonged (prenatal and postnatal) gonadotropin deficiency in women with IHH/KS might also have a more pronounced impact on ovarian follicle development and, thus, on AMH secretion than would an acquired deficit. This is consistent with results from Deubzer et al. (27) , who reported very low AMH levels in three teenage girls with severe congenital panhypopituitarism, whereas girls with global hypopituitarism acquired after birth had AMH levels closer to those of healthy women.
Average OV was significantly less in women with IHH/KS than in the healthy controls and similar to ovarian healthy prepubertal girls (19) . The low OV observed in this study is in agreement with that reported by Shaw et al. (2) in 39 women with IHH/KS. We also found that the subgroup of women with the lowest FSH concentrations had the smallest ovaries.
In this study, we determined the number of AFs in a significant number of women with IHH/KS. The total AF number per ovary was lower than in healthy controls studied with the same ultrasound method. Low follicle counts appear to be related to the severity of gonadotropin (especially FSH) deficiency, as the subgroup of women with the lowest FSH levels had also the lowest counts. However, the number of larger follicles was more severely affected than the number of smaller follicles. This suggests that the FSH deficit in women with IHH/KS preferentially affects terminal follicle development responsible for larger follicles and is consistent with published data showing that the development of larger follicles, as well as the selection of a dominant follicle, requires sufficient, near-normal FSH secretion (28) . The relative sparing of small follicles suggests that a degree of follicle growth can occur despite very inadequate FSH secretion, as was also true in a woman with isolated FSH deficiency due to mutation of the FSH-b subunit gene (4) . The lower number of small AFs among IHH/KS women than among healthy controls suggests that follicle growth to the small antral stage also requires a certain threshold level of FSH secretion. The total AF number in patients with IHH/KS may be even lower than that reported in prepubertal girls measured using ovarian MRI (19) . Although this difference may suggest a specific ovarian impact of both prenatal and early postnatal gonadotropin deficiency as is seen in men with IHH/KS (3), confirmation requires comparisons using the same methodology in both groups.
As expected, rhFSH administration caused a significant increase in E2 (4) (5) (6) (7) (8) . It is noteworthy that the E2 elevation was smaller than that described in similar patients treated concomitantly with rhFSH and recombinant LH (12, 13) . rhFSH stimulation also allowed us to specify, in vivo, the relationship between the growth of ovarian follicles and the secretion of InhB and AMH. The sharp increase in InhB levels coincided with the increase in the number of large (.6 mm) AFs. This is in agreement with reports that InhB is secreted by granulosa cells present in larger dominant follicles (24, 29, 30) . However, it is noteworthy that E2 and larger AFs increased despite a decrease in FSH doses whereas InhB increased and then plateaued. These data suggest that terminal follicular growth and E2 secretion by the larger AFs could require less FSH than InhB secretion.
Interestingly, in IHH/KS, circulating AMH levels increased rapidly after rhFSH stimulation. This strongly suggests that FSH plays a role in ovarian AMH secretion. Even more interestingly, we found that serum AMH levels normalized in most IHH/KS women treated with rhFSH, showing that the low basal AMH levels in these patients are reversible. The relatively early increase in AMH was associated with an early increase in the overall number of AFs and in particular those #6 mm. The subsequent decrease in AMH levels and small follicle number could be related to the decreased FSH doses administered. Alternatively, and most likely, the delayed decrease in AMH levels could mainly be related to the relative increase in the number of large AFs gradually induced by rhFSH therapy. This latter hypothesis is in agreement with both the demonstrated negative correlation between human follicular fluid AMH concentrations and the increase in size of AFs and also with the decrease in AMH levels observed during puberty (24, 30, 31) .
For clinical and therapeutic purposes, it was important to show in this study that the low AMH levels and low AFCs in women with IHH/KS can be reversed by FSH administration, and that fertility can be achieved despite data suggesting an "impaired ovarian reserve." The low AMH levels and low AFCs in women with complete IHH/KS should therefore not be considered predictive of a poor response to ovarian stimulation with gonadotropins, or as a sign of a poor fertility prognosis. Indeed, it is clearly established that, in the vast majority of cases, ovulation and fertility can be achieved by pulsatile GnRH administration or by gonadotropin combination therapy in these patients (12, 13, 32) .
Conclusion
In this study, we show that women with IHH/KS have variably low circulating AMH levels, and that the severity of AMH deficiency is related to the severity of FSH deficiency. Additionally, the low AMH levels in these patients are associated with low AFCs. However, both of these latter parameters can be reversed by FSH administration. These patients' low OV, low AMH, and/or AFC should not be considered to indicate a poor childbearing prognosis, as fertility can be effectively restored by both pulsatile GnRH and gonadotropin administration.
